MXPA05010793A - Beta-carbolinas utiles para tratar enfermedades inflamatorias. - Google Patents

Beta-carbolinas utiles para tratar enfermedades inflamatorias.

Info

Publication number
MXPA05010793A
MXPA05010793A MXPA05010793A MXPA05010793A MXPA05010793A MX PA05010793 A MXPA05010793 A MX PA05010793A MX PA05010793 A MXPA05010793 A MX PA05010793A MX PA05010793 A MXPA05010793 A MX PA05010793A MX PA05010793 A MXPA05010793 A MX PA05010793A
Authority
MX
Mexico
Prior art keywords
beta
inflammatory disease
treating inflammatory
useful
carbolines
Prior art date
Application number
MXPA05010793A
Other languages
English (en)
Inventor
Ye Yingchun
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Publication of MXPA05010793A publication Critical patent/MXPA05010793A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Abstract

Esta invencion proporciona compuestos beta-carbolina de formula I: (ver formula I) donde el Anillo A es un anillo piridinilo, pirimidinilo, morfolinilo, piperidinilo, piperazinilo, pirrolidinilo, piranilo, tetrahidrofuranoilo, ciclohexilo, ciclopentilo o tiomorfolinilo sustituido y R1, R2 y R3 son como se han definido en la memoria descriptiva. Los compuestos son inhibidores de IKK-2 que son utiles para tratar enfermedades mediadas por IKK-2 tales como enfermedades inflamatorias y cancer.
MXPA05010793A 2003-04-09 2004-04-09 Beta-carbolinas utiles para tratar enfermedades inflamatorias. MXPA05010793A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46146803P 2003-04-09 2003-04-09
PCT/US2004/011080 WO2004092167A1 (en) 2003-04-09 2004-04-09 Beta-carbolines useful for treating inflammatory disease

Publications (1)

Publication Number Publication Date
MXPA05010793A true MXPA05010793A (es) 2005-12-05

Family

ID=33299818

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05010793A MXPA05010793A (es) 2003-04-09 2004-04-09 Beta-carbolinas utiles para tratar enfermedades inflamatorias.

Country Status (22)

Country Link
US (2) US7727985B2 (es)
EP (1) EP1611134A1 (es)
JP (1) JP2006522824A (es)
KR (1) KR20060006031A (es)
CN (1) CN1802375A (es)
AU (1) AU2004230952A1 (es)
BR (1) BRPI0409263A (es)
CA (1) CA2521300A1 (es)
CO (1) CO5700746A2 (es)
CR (1) CR8042A (es)
EA (1) EA009121B1 (es)
EC (1) ECSP056145A (es)
HR (1) HRP20050926A2 (es)
MA (1) MA27837A1 (es)
MX (1) MXPA05010793A (es)
NI (1) NI200500174A (es)
NO (1) NO20054598L (es)
OA (1) OA13115A (es)
RS (1) RS20050832A (es)
TN (1) TNSN05257A1 (es)
WO (1) WO2004092167A1 (es)
ZA (1) ZA200508198B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA05010793A (es) 2003-04-09 2005-12-05 Millennium Pharm Inc Beta-carbolinas utiles para tratar enfermedades inflamatorias.
TW200539880A (en) * 2004-04-09 2005-12-16 Millennium Pharm Inc Beta-carbolines useful for treating inflammatory disease
US8119655B2 (en) * 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
CA2630562C (en) 2005-11-22 2013-12-31 Merck & Co., Inc. Tricyclic compounds useful as inhibitors of kinases
WO2007106884A2 (en) 2006-03-15 2007-09-20 Theralogics, Inc. Methods of treating muscular wasting diseases using nf-kb activation inhibitors
WO2008002246A1 (en) * 2006-06-28 2008-01-03 Astrazeneca Ab A pharmaceutical composition comprising an ikk2 inhibitor and a second active ingrdient.
AR064307A1 (es) * 2006-12-13 2009-03-25 Gilead Sciences Inc Monofosfatos utiles para el tratamiento de la inflamacion pulmonar y broncoconstriccion, formulaciones aerosolicas que los contienen, y metodo de preparacion.
WO2009054965A1 (en) * 2007-10-23 2009-04-30 Millennium Pharmaceuticals, Inc. Salts of n- (6-chloro-9h-pyrido [3,4-b] ind0l-8-yl) -4- [2- (2, 6-dimethyl-4-morpholinyl) -2-0x0e thyl] -6, 6-dimethyl-morpholinecarboxamide
WO2009054970A1 (en) * 2007-10-23 2009-04-30 Millennium Pharmaceuticals, Inc. Mesylate salt of an ikk inhibitor
EP2297347B1 (en) 2008-05-14 2017-03-08 Millennium Pharmaceuticals, Inc. Methods and kits for monitoring the effects of immunomodulators on adaptive immunity
US8299055B2 (en) 2008-10-02 2012-10-30 Asahi Kasei Pharma Corporation 8-substituted isoquinoline derivative and the use thereof
WO2011120911A1 (en) 2010-03-30 2011-10-06 Novartis Ag Pkc inhibitors for the treatment of b-cell lymphoma having chronic active b-cell-receptor signalling
KR101784284B1 (ko) * 2011-03-28 2017-10-11 에스제이티 몰레큘라 리서치, 에스.엘. 대사증후군 치료 화합물
CN102416014B (zh) * 2011-09-13 2012-11-21 河南中医学院 一种生物碱类成分组合物在制备抗甲型h1n1流感病毒药物中的应用
CN102391323B (zh) * 2011-10-18 2013-09-25 首都医科大学 四氢-β-咔啉衍生物、其制备方法及其用途
KR101646916B1 (ko) 2015-07-13 2016-08-09 강원대학교산학협력단 베타-카르볼린 알칼로이드 화합물을 함유하는 염증성 질환의 예방 또는 치료용 조성물
CN108271369A (zh) 2015-10-23 2018-07-10 法尔玛赞公司 用于制备色胺及其衍生物的新工艺
CN109593089B (zh) * 2019-01-24 2022-01-28 西南大学 二氮杂螺癸烷哌啶甲酰胺类化合物制备和应用
CN112824387B (zh) * 2019-11-21 2023-03-21 济南尚博生物科技有限公司 一种2-甲基烟酸酯及其制备方法和应用
CN117510494B (zh) * 2023-11-07 2024-04-19 桂林医学院附属医院 β-咔啉-沙利度胺偶联物及其在制备逆转ABT-199耐药的药物中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69925840T2 (de) * 1998-08-12 2006-05-04 Pfizer Products Inc., Groton Tace inhibitoren
DE19951360A1 (de) 1999-10-26 2001-05-03 Aventis Pharma Gmbh Substituierte Indole
BR0109161A (pt) 2000-03-15 2002-11-26 Aventis Pharma Gmbh Beta-carbolinas substituìdas com atividade de inibição de ikb-quinase
WO2001068648A1 (en) * 2000-03-15 2001-09-20 Aventis Pharma Deutschland Gmbh Substituted beta-carbolines with ikb-kinase inhibiting activity
CA2460939C (en) * 2001-09-19 2008-07-29 Pharmacia Corporation Substituted pyrazolyl compounds for the treatment of inflammation
WO2003039545A2 (en) * 2001-11-07 2003-05-15 Millennium Pharmaceuticals, Inc. Carboline derivatives as inhibitors of ikb in the treatment of multiple myeloma and others cancers
JP2006519855A (ja) * 2003-03-07 2006-08-31 イーライ リリー アンド カンパニー オピオイド受容体アンタゴニスト
MXPA05010793A (es) 2003-04-09 2005-12-05 Millennium Pharm Inc Beta-carbolinas utiles para tratar enfermedades inflamatorias.

Also Published As

Publication number Publication date
NO20054598L (no) 2005-10-27
EA200501584A1 (ru) 2006-06-30
CR8042A (es) 2006-05-30
EA009121B1 (ru) 2007-10-26
WO2004092167A1 (en) 2004-10-28
BRPI0409263A (pt) 2006-03-28
EP1611134A1 (en) 2006-01-04
OA13115A (en) 2006-11-10
CA2521300A1 (en) 2004-10-28
TNSN05257A1 (en) 2007-07-10
JP2006522824A (ja) 2006-10-05
MA27837A1 (fr) 2006-04-03
WO2004092167A8 (en) 2006-01-05
US7727985B2 (en) 2010-06-01
US20040235839A1 (en) 2004-11-25
KR20060006031A (ko) 2006-01-18
ZA200508198B (en) 2007-01-31
US20100093713A1 (en) 2010-04-15
ECSP056145A (es) 2006-04-19
AU2004230952A1 (en) 2004-10-28
CO5700746A2 (es) 2006-11-30
HRP20050926A2 (en) 2006-06-30
NO20054598D0 (no) 2005-10-06
CN1802375A (zh) 2006-07-12
NI200500174A (es) 2006-04-17
RS20050832A (en) 2007-12-31

Similar Documents

Publication Publication Date Title
TNSN05257A1 (en) Beta-carbolines useful for treating inflammatory disease
IL172942A0 (en) Pyrazoloisoquinoline derivatives as kinase inhibitors
TNSN06321A1 (en) Beta-carbolines useful for treating inflammatory disease
NZ542616A (en) P38 inhibitors and methods of use thereof
TNSN07323A1 (en) Imidazo (1, 2-a) pyridine compounds as vegf-r2 inhibitors
HRP20110566T8 (en) Azaindoles useful as inhibitors of jak and other protein kinases
ATE339418T1 (de) Thiazolverbindungen, die sich als inhibitoren von proteinkinasen eignen
NO20082594L (no) Pyrimidinylbenzotiofenforbindelser
NO20063479L (no) Fosfonater, monofosfonamidater og bis-fosfonamidater for behandling av virussykdommer
SE0301700D0 (sv) Novel compounds
TW200700422A (en) Compounds for inhibiting ksp kinesin activity
MXPA04002682A (es) Compuestos pirazolilo sustituidos para el tratamiento de la inflamacion.
TW200510407A (en) Novel pyrrolodihydroisoquinolines as PDE 10 inhibitors
TW200738659A (en) Novel compounds
TW200700066A (en) Compounds for inhibiting ksp kinesin activity
TW200700064A (en) Novel compounds
MX2023004518A (es) Compuestos espiro heterocíclicos y métodos de uso.
TW200505443A (en) Combination of SCR kinase inhibitors and chemotherapeutic agents for the treatment of proliferative diseases
BR0318521A (pt) arilindenopiridinas e arilindenopirimidinas e métodos terapêuticos e profiláticos relacionados
TW200510427A (en) Novel fused heterocycles and uses thereof
DE60316128D1 (de) N-sulfonylurea-apoptosis-förderer
ATE419242T1 (de) Pyrrolidinylharnstoffderivate als angiogeneseinhibitoren
HK1074840A1 (en) Novel dithiolopyrrolones with therapeutic activity
MXPA03011167A (es) Derivados de carbolina utiles como ihibidores de pdev.
UA84016C2 (ru) Бета-карболины, полезные для лечения воспалительных заболеваний, фармацевтическая композиция на их основе

Legal Events

Date Code Title Description
FG Grant or registration